Hims and Hers (HIMS -2.89%) just posted a jaw-dropping 143% stock gain and a $586 million quarter -- but Wall Street says "hold." Between booming GLP-1 sales, Food and Drug Administration (FDA) pressure, and a controversial ad blitz, the real story is anything but boring. Could this be the next massive health-tech winner?
Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 9, 2025.